Evidence map›Paper›PMID 37658305›Full record

Trial reportBMC infectious diseases2023

Evaluating the impact of point-of-care HIV viral load assessment on linkage to care in Baltimore, MD: a randomized controlled trial.

Mohammad Harris Bayan, Travis Smalls, Alec Boudreau, Agha W Mirza, Courtney Pasco, Zoe O Demko, Richard E Rothman, Yu-Hsiang Hsieh, Susan H Eshleman, Heba H Mostafa and 8 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04793750 (Ending the HIV Epidemic Through Point-of-Care Technologies), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04793750 nacompletednot on this map

Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC): Performance Evaluation of Novel POC HIV Tests in Baltimore

TypeinterventionalSponsorJohns Hopkins UniversityRan2021 to 2025Enrolled224ConditionsHIV Infections, SyphilisArmsCepheid GeneXpert HIV-1 Qual POC HIV VL test, DPP HIV-Syphilis test system, OraQuick
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Mohammad Harris BayanDivision of Infectious Diseases, Johns Hopkins University, Baltimore, MD, USA.
Travis SmallsDivision of Infectious Diseases, Johns Hopkins University, Baltimore, MD, USA.
Alec BoudreauDivision of Infectious Diseases, Johns Hopkins University, Baltimore, MD, USA.
Agha W MirzaDivision of Infectious Diseases, Johns Hopkins University, Baltimore, MD, USA.
Courtney PascoDivision of Infectious Diseases, Johns Hopkins University, Baltimore, MD, USA.
Zoe O DemkoDivision of Infectious Diseases, Johns Hopkins University, Baltimore, MD, USA.
Richard E RothmanDivision of Infectious Diseases, Johns Hopkins University, Baltimore, MD, USA.
Yu-Hsiang HsiehDepartment of Emergency Medicine, Johns Hopkins University, Baltimore, MD, USA.
Susan H EshlemanDepartment of Pathology, Johns Hopkins University, Baltimore, MD, USA.
Heba H MostafaDepartment of Pathology, Johns Hopkins University, Baltimore, MD, USA.
Nathalie Gonzalez-JimenezCenters for Disease Control and Prevention, Atlanta, GA, USA.
Pollyanna R ChavezCenters for Disease Control and Prevention, Atlanta, GA, USA.
Brian EmersonCenters for Disease Control and Prevention, Atlanta, GA, USA.
Kevin P DelaneyCenters for Disease Control and Prevention, Atlanta, GA, USA.
Debra DaughertyDLH Corporation, Atlanta, GA, USA.
Robin J MacGowanCenters for Disease Control and Prevention, Atlanta, GA, USA.
Yukari C ManabeDivision of Infectious Diseases, Johns Hopkins University, Baltimore, MD, USA.
Matthew M HamillDivision of Infectious Diseases, Johns Hopkins University, Baltimore, MD, USA. mhamill6@jhu.edu.
Johns Hopkins University · USCenters for Disease Control and Prevention · US

Funding

LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
CDC HHS U01PS005204-01-00NCHHSTP CDC HHS U01 PS005204NIAID NIH HHS UM1 AI068613
6 · The paper itself

Abstract

backgroundIntegration of a sensitive point-of-care (POC) HIV viral load (VL) test into screening algorithms may help detect acute HIV infection earlier, identify people with HIV (PWH) who are not virally suppressed, and facilitate earlier referral to antiretroviral therapy (ART), or evaluation for pre-exposure prophylaxis (PrEP). This report describes a randomized clinical trial sponsored by the Centers for Disease Control and Prevention (CDC): "Ending the HIV Epidemic Through Point-of-Care Technologies" (EHPOC). The study's primary aim is to evaluate the use of a POC HIV VL test as part of a testing approach and assess the impact on time to linkage to ART or PrEP. The study will recruit people in Baltimore, Maryland, including patients attending a hospital emergency department, patients attending an infectious disease clinic, and people recruited via community outreach. The secondary aim is to evaluate the performance characteristics of two rapid HIV antibody tests approved by the United States Food and Drug Administration (FDA).

methodsThe study will recruit people 18 years or older who have risk factors for HIV acquisition and are not on PrEP, or PWH who are not taking ART. Participants will be randomly assigned to either the control arm or the intervention arm. Participants randomized to the control arm will only receive the standard-of-care (SOC) HIV screening tests. Intervention arm participants will receive a POC HIV VL test in addition to the SOC HIV diagnostic screening tests. Follow up will consist of an interim phone survey conducted at week-4 and an in-person week-12 visit. Demographic and behavioral information, and oral fluid and blood specimens will be collected at enrollment and at week-12. Survey data will be captured in a Research Electronic Data Capture (REDCap) database. Participants in both arms will be referred for either ART or PrEP based on their HIV test results. DISCUSSION: The EHPOC trial will explore a novel HIV diagnostic technology that can be performed at the POC and provide viral assessment. The study may help inform HIV testing algorithms and contribute to the evidence to support same day ART and PrEP recommendations.

trial registrationNIH ClinicalTrials.gov NCT04793750. Date: 11 March 2021.

Indexed as

HIV InfectionsPoint-of-Care SystemsBaltimoreHIV TestingHumansUnited StatesViral LoadAcute HIV infectionAntiretroviral therapyDiagnosticsHIVLinkage-to-carePoint-of-carePre-exposure prophylaxisRandomized clinical trialViral load testing

Identifiers

PMID37658305
PMCPMC10474693
OpenAlexW4386370641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.